Compass Pathways (NASDAQ:CMPS) Announces Earnings Results

Compass Pathways (NASDAQ:CMPS) posted its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.08, Zacks reports.

Here are the key takeaways from Compass Pathways’ conference call:

• COMPASS expects to complete its rolling NDA submission for COMP360 within two weeks. The National Priority Voucher could support an FDA review target of roughly one to two months, although approval timing remains uncertain.
• The company reported strong commercial-launch preparation for a potential first-half 2027 TRD launch, including filled non-field commercial roles, expanding field-force recruitment, payer discussions, and engagement with more than 8,500 interventional psychiatry centers.
• Management highlighted COMP360’s reported rapid onset, durability potentially extending to 12 months, and infrequent dosing as key differentiators from existing treatment options. Market research found approximately 90% of surveyed interventional psychiatrists would prescribe it within the first year, though these findings reflect company-sponsored research.
• COMPASS said its PTSD registrational study is actively enrolling and identified additional potential expansion areas, including substance-use disorders, bipolar II disorder, and OCD. The company remains focused primarily on the TRD launch, with PTSD described as the next major indication opportunity.
• Launch execution still depends on DEA and state-level rescheduling, REMS implementation, reimbursement, and provider training. CPT Category III codes may take 12–18 months to transition to Category I, prompting planned patient-support and site-support programs to reduce early access and affordability barriers.

Compass Pathways Stock Up 0.4%

NASDAQ:CMPS traded up $0.04 during midday trading on Wednesday, reaching $8.63. The company had a trading volume of 3,711,323 shares, compared to its average volume of 3,500,006. Compass Pathways has a 12-month low of $4.88 and a 12-month high of $15.87. The stock’s fifty day simple moving average is $12.70 and its 200-day simple moving average is $10.39. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -1.87 and a beta of 2.43.

Analyst Ratings Changes

Several equities research analysts have recently commented on CMPS shares. Stifel Nicolaus boosted their price objective on Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Morgan Stanley upped their price target on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Evercore raised Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price for the company in a research report on Wednesday, July 8th. BTIG Research reissued a “buy” rating and set a $25.00 price objective on shares of Compass Pathways in a report on Tuesday. Finally, HC Wainwright cut their price objective on shares of Compass Pathways from $70.00 to $65.00 and set a “buy” rating for the company in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Compass Pathways currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.14.

Key Stories Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: COMPASS said it expects to complete its New Drug Application for COMP360 within two weeks and outlined a potential 30- to 60-day FDA review timeline. A survey of interventional psychiatrists also found that 90% would be willing to prescribe COMP360, suggesting potential adoption if approved. Article: Compass Pathways: 3 Key Takeaways for Long-Term Investors Article: COMPASS outlines FDA review target
• Positive Sentiment: Third-quarter loss was $0.31 per share, narrower than analysts’ $0.39 estimate, providing a modest earnings catalyst. Article: Compass Pathways Q3 2026 earnings
• Positive Sentiment: Analyst support remains: BTIG reaffirmed its Buy rating with a $25 target, and Oppenheimer reiterated Outperform. Jefferies also said robust clinical data could support pricing power. BTIG rating Oppenheimer rating
• Negative Sentiment: Wells Fargo cut its price target from $13 to $10 and maintained an Equal Weight rating, signaling more restrained upside expectations. Wells Fargo rating
• Negative Sentiment: Competitive pressure remains a risk after a rival’s NDA submission triggered a selloff in CMPS. The competing FDA race could affect expectations for COMP360’s timing and commercial prospects, despite Stifel describing the Usona situation as atypical. Article: COMPASS rebounds on earnings after rival NDA selloff Stifel comment on Usona

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.